Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics

DOI10.1111/BIOM.13433zbMath1520.62210arXiv2011.11480OpenAlexW3127736510MaRDI QIDQ6079344

Marie-Karelle Riviere, Unnamed Author, Moreno Ursino, Unnamed Author, Unnamed Author, Sarah Zohar

Publication date: 30 October 2023

Published in: Biometrics (Search for Journal in Brave)

Full work available at URL: https://arxiv.org/abs/2011.11480

zbMATH Keywords

hierarchical modelBayesian inferencetoxicitypharmacokinetics/pharmacodynamicsdose regimenearly phase oncology

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites Work

• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within Patients
• Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes
• Design and Analysis of Phase I Clinical Trials
• Statistical Methods for Dose‐Finding Experiments
• Determining the Effective Sample Size of a Parametric Prior
• Dose‐finding methods for Phase I clinical trials using pharmacokinetics in small populations
• Handbook of Statistics in Clinical Oncology
• Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent
• Prior distributions for variance parameters in hierarchical models (Comment on article by Browne and Draper)

This page was built for publication: Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics